OrsoBio
CompanyUnited States
OrsoBio develops one asset, in phase 2 (TLC-6740 in obesity). Mostly small molecule acting on oxidative phosphorylation; based in the United States.
- 1
- Asset
- Furthest stage
- Phase 2
- 1
- Trial
- 1
- Signal
Pipeline
1Uncouples mitochondrial oxidative phosphorylation in the liver to increase energy expenditure.
Phase 2, Small molecule, Oxidative phosphorylation, obesity
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms2
- Trials1
- Signals2
- Similar companies6
Papers
ADA Scientific Sessions 2026 abstract, 6 Jun 2026